Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02139124 · ClinicalTrials.gov registry record · Phase 3
The Efficacy and Safety of PRC-063 in Adult ADHD Patients
A Phase 3 study, sponsored by Rhodes Pharmaceuticals, L.P..
- Completed
- Registry status
- Phase 3
- Development phase
- 375
- Enrollment target
NCT02139124 is a Phase 3 study that has completed, run by Rhodes Pharmaceuticals, L.P.. The registered enrollment target is 375 participants.
The verdict
NCT02139124, a Phase 3 study, has completed, sponsored by Rhodes Pharmaceuticals, L.P..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 375 participants
- Enrollment target
Study Summary
The purpose of this randomized, placebo-controlled, double-blind, parallel group study is to evaluate the clinical efficacy and safety of PRC-063 in adults with ADHD
Interventions
- DRUG Placebo
- DRUG PRC-063 25 mg
- DRUG PRC-063 45 mg
- DRUG PRC-063 70 mg
- DRUG PRC-063 100 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2014-04 |
| Est. Completion | 2015-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02139124
The ClinicalTrials.gov registry entry for NCT02139124 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 375 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rhodes Pharmaceuticals, L.P., which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02139124 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02139124 about?
NCT02139124 is a clinical study titled "The Efficacy and Safety of PRC-063 in Adult ADHD Patients". The purpose of this randomized, placebo-controlled, double-blind, parallel group study is to evaluate the clinical efficacy and safety of PRC-063 in adults with ADHD
What is the current status of trial NCT02139124?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 375 participants. The study started on 2014-04. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02139124?
The interventions under investigation include: Placebo (DRUG), PRC-063 25 mg (DRUG), PRC-063 45 mg (DRUG), PRC-063 70 mg (DRUG), PRC-063 100 mg (DRUG).
Who is sponsoring clinical trial NCT02139124?
This trial is sponsored by Rhodes Pharmaceuticals, L.P., which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.